{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:46:28Z","timestamp":1778028388158,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T00:00:00Z","timestamp":1573257600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T00:00:00Z","timestamp":1573257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Key R&D Program of China","award":["(2018YFC1314700)"],"award-info":[{"award-number":["(2018YFC1314700)"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81500970"],"award-info":[{"award-number":["81500970"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81500970"],"award-info":[{"award-number":["81500970"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"publisher","award":["(16CR3009A)."],"award-info":[{"award-number":["(16CR3009A)."]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key R&D Program of China","award":["2018YFC1314700"],"award-info":[{"award-number":["2018YFC1314700"]}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"crossref","award":["16CR3009A"],"award-info":[{"award-number":["16CR3009A"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00702-019-02100-1","type":"journal-article","created":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T18:02:53Z","timestamp":1573322573000},"page":"1625-1629","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparing lanbotulinumtoxinA (Hengli\u00ae) with onabotulinumtoxinA (Botox\u00ae) and incobotulinumtoxinA (Xeomin\u00ae) in the mouse hemidiaphragm assay"],"prefix":"10.1007","volume":"126","author":[{"given":"Lizhen","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Bigalke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingjing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Dressler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,9]]},"reference":[{"key":"2100_CR1","first-page":"493","volume":"86","author":"MF Brin","year":"1993","unstructured":"Brin MF, Blitzer A (1993) Botulinum toxin: dangerous terminology errors J Roy Soc Med 86:493\u2013494","journal-title":"Botulinum toxin: dangerous terminology errors J Roy Soc Med"},{"key":"2100_CR2","first-page":"38","volume":"1","author":"E Buelbring","year":"1946","unstructured":"Buelbring E (1946) Observation on the isolated phrenic nerve diaphragm preparation in the rat. Br J Pharmacol 1:38\u201361","journal-title":"Br J Pharmacol"},{"issue":"suppl 2","key":"2100_CR3","first-page":"18","volume":"15","author":"D Dressler","year":"2000","unstructured":"Dressler D, Dirnberger G, Bhatia K, Quinn NP, Irmer A, Bigalke H (2000) Botulinum toxin antibody testing: comparison of the mouse diaphragm bioassay and the mouse lethality bioassay. Mov Disord 15(suppl 2):18\u201319","journal-title":"Mov Disord"},{"key":"2100_CR4","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00702-018-1897-x","volume":"125","author":"D Dressler","year":"2018","unstructured":"Dressler D, Pan L, Bigalke H (2018) Comparing incobotulinumtoxinA (Xeomin\u00ae) and onabotulinumtoxinA (Botox\u00ae): identical potency labelling in the hemidiaphragm assay. J Neural Transm 125:1351\u20131354","journal-title":"J Neural Transm"},{"key":"2100_CR5","unstructured":"Dressler D, Pan L, Su J, Teng F, Jin L (in press) Lantox\u2014the Chinese Botulinum Toxin Drug. Complete English Bibliography and Formalised Literature Review. Park Rel Disord"},{"key":"2100_CR6","unstructured":"European Pharmacopoeia 6.0 (2008a) Botulinum Toxin Type A for Injection, 1327\u20131329"},{"key":"2100_CR7","unstructured":"European Pharmacopoeia 6.0 (2008b) Statistical Analysis of Biological Assays and Tests 5.3: 571\u2013600"},{"key":"2100_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1006\/exnr.1997.6580","volume":"147","author":"H Goeschel","year":"1997","unstructured":"Goeschel H, Wohlfahrt K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin: neutralizing and nonneutralizing antibodies\u2014therapeutic consequences. Exp Neurol 147:96\u2013102","journal-title":"Exp Neurol"},{"key":"2100_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/dsu.12405","volume":"40","author":"HY Jiang","year":"2014","unstructured":"Jiang HY, Chen S, Zhou J, Leung KK, Yu P (2014) Diffusion of two botulinum toxins type A on the forehead: double-blinded, randomized, controlled study. Dermatol Surg 40:184\u2013192","journal-title":"Dermatol Surg"},{"key":"2100_CR10","first-page":"150","volume":"22","author":"HY Jiang","year":"2016","unstructured":"Jiang HY, Chen S, Zhou J (2016) Diffusion comparison of two botulinum toxin A preparations in the forehead. Chin J Med Aesth Cosmetol 22:150\u2013153 (In Chinese)","journal-title":"Chin J Med Aesth Cosmetol"},{"key":"2100_CR11","unstructured":"JASP Team (2019) JASP (Version 0.9.2)"},{"key":"2100_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/jnnp.59.1.102","volume":"59","author":"MH Marion","year":"1995","unstructured":"Marion MH, Sheehy M, Sangla S, Soulayrol S (1995) Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiat 59:102\u2013103","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"2100_CR13","first-page":"494","volume":"86","author":"CD Marsden","year":"1993","unstructured":"Marsden CD (1993) Botulinum toxin: dangerous terminology errors J Roy Soc Med 86:494","journal-title":"Botulinum toxin: dangerous terminology errors J Roy Soc Med"},{"key":"2100_CR14","first-page":"216","volume":"11","author":"O Oliveira de Morais","year":"2012","unstructured":"Oliveira de Morais O, Matos Reis-Filho E, Vilela Pereira L, Martins Gomes C, Alves G (2012) Comparison of four botulinum neurotoxin type A preparations in the treatment of hyperdynamic forehead lines in men: a pilot study. J Drugs Dermatol 11:216\u2013219","journal-title":"J Drugs Dermatol"},{"key":"2100_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1006\/taap.1994.1181","volume":"128","author":"LB Pearce","year":"1994","unstructured":"Pearce LB, Borodic GE, First ER, MacCallum RD (1994) Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 128:69\u201377","journal-title":"Toxicol Appl Pharmacol"},{"key":"2100_CR16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/WNF.0b013e3181c46f61","volume":"33","author":"EM Quagliato","year":"2010","unstructured":"Quagliato EM, Carelli EF, Viana MA (2010) Prospective, randomised, double-blind study comparing botulinum toxins type a Botox and Prosigne for blepharospasm and hemifacial spasm treatment. Clin Neuropharmacol 33:27\u201331","journal-title":"Clin Neuropharmacol"},{"key":"2100_CR17","first-page":"459","volume":"72","author":"D Ranoux","year":"2002","unstructured":"Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M (2002) Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72:459\u2013462","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2100_CR18","first-page":"794","volume":"113","author":"XF Tang","year":"2000","unstructured":"Tang XF, Wan XH (2000) Comparison of botox with Chinese type A botulinum. Chin Med J (Engl) 113:794\u2013798","journal-title":"Chin Med J (Engl)"},{"key":"2100_CR19","first-page":"135","volume":"32","author":"XF Tang","year":"1999","unstructured":"Tang XF, Wan XH, Huang G, Zhang QB, Li T (1999) The treatment of focal dystonia and muscle spasms with Botox and CBTX-A. Chin J Neurol 32:135\u2013138 (In Chinese)","journal-title":"Chin J Neurol"},{"key":"2100_CR20","first-page":"30","volume-title":"3rd International dystonia symposium, October 9\u201311, 1996, Miami, Florida","author":"P Van den Bergh","year":"1996","unstructured":"Van den Bergh P, Lison D, Dose standardisation of BTX (1996) 3rd International dystonia symposium, October 9\u201311, 1996, Miami, Florida. Affiliated National Dystonia Associations, Chicago, p 30"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-019-02100-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-019-02100-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-019-02100-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T06:23:09Z","timestamp":1664864589000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-019-02100-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,9]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2100"],"URL":"https:\/\/doi.org\/10.1007\/s00702-019-02100-1","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,9]]},"assertion":[{"value":"13 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DD received honoraria for consultations from Allergan, Ipsen, IAB-Interdisciplinary Working Group for Movement Disorders, Merz and Syntaxin. He is a shareholder of Allergan. He holds patents in botulinum toxin research and provides professional consulting services to pharmaceutical companies and professional investment institutions on all aspects of botulinum toxin drugs. HB is the founder and co-owner of Toxogen. LP, BK and LJ have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}